Rearming the body’s immune system to fight cancer

We’re developing more precise and more accessible treatment alternatives for patients with solid cancers

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Learn more about us

Some of our partners

Latest news

The Social Costs of Delaying Effective Cancer Treatment Using CAR-T Immunotherapy

By Karen Loudon / September 5, 2019
CAR-T therapy can save lives and boost benefits to society … if it’s delivered promptly, says Cartherics CEO and Executive...
Read More

MEETING ON THE MESA: Cartherics heads to California

By Karen Loudon / September 3, 2019
By Leigh Dayton, 2 September 2019 Cartherics has been invited to present at the prestigious Cell & Gene Meeting on...
Read More

Flow cytometry: The core characterisation technique for developing next-generation cancer immunotherapies

By Karen Loudon / August 28, 2019
CAR-T immunotherapy involves genetically engineering T-cells with chimeric antigen receptors (CARs). FLOW cytometry uses antibodies tagged with fluorescent markers that...
Read More